10-Q: AngioDynamics Reports Revenue Growth, Margin Improvement

AngioDynamics announced a 6.9% increase in net sales to $80.9 million for the first quarter of fiscal year 2027, alongside a 410 basis point improvement in gross margin to 59.4%, though the company still reported a net loss.

Summary

• AngioDynamics reported net sales of $80.9 million for the three months ended August 31, 2026, a 6.9% increase compared to $75.7 million in the prior year period.
• Gross margin improved by 410 basis points to 59.4% ($48.0 million) from 55.3% ($41.9 million) in the prior year.
• Net loss for the quarter was $7.1 million, or $0.17 per diluted share, an improvement from a net loss of $10.9 million, or $0.26 per diluted share, in the same period last year.
• Operating expenses increased to $55.3 million from $52.5 million, primarily driven by higher research and development and sales and marketing costs.
• The company ended the quarter with $34.0 million in cash and cash equivalents.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with revenue growth and improved gross margins offset by continued net losses and significant operating expenses.

Positives

• Net sales increased by 6.9% to $80.9 million, driven by growth in both Med Tech and Med Device segments.
• Gross margin improved significantly by 410 basis points to 59.4%, with Med Tech margins at 66.2% and Med Device at 52.7%.
• Net loss decreased by $3.8 million to $7.1 million compared to the prior year's quarter.
• Loss per share improved to $0.17 from $0.26 in the prior year period.
• Med Tech segment net sales grew by 13.2%, with notable increases in Auryon, NanoKnife, and thrombus management products.
• Med Device segment net sales saw a modest increase of 1.4%, with growth in Core and Microwave product lines.

Negatives

• The company continues to report a net loss of $7.1 million for the quarter.
• Operating expenses increased by $2.8 million to $55.3 million, largely due to higher R&D and S&M spending.
• Cash and cash equivalents decreased to $34.0 million from $53.9 million at the end of the previous fiscal quarter.
• Cash used in operating activities was $15.3 million, a slight improvement from $15.9 million in the prior year, but still a significant outflow.
• Inventories increased by $2.5 million, and accounts payable and accrued liabilities decreased by $17.4 million, negatively impacting working capital.

Risks

• The company faces risks related to technological advances and patents of competitors, and potential infringement of its own technology.
• Competition from companies with substantially greater resources is a significant challenge.
• Future actions by the FDA or other regulatory agencies could impact the business.
• Changes in domestic and foreign healthcare reforms and government regulations pose a risk.
• Results of pending or future clinical trials are uncertain.
• Overall economic conditions, including inflation, tariffs, labor shortages, and supply chain challenges, could adversely affect results.
• Ongoing litigation and challenges with third-party distributors or collaborators present risks.
• Product recalls and product liability claims could materially impact financial condition.

Future Outlook

The company expects to grow in both sales and profitability by expanding geographically, penetrating new markets, introducing new products, and increasing its international presence. Management believes current cash on hand provides sufficient liquidity for at least the next 12 months, but may require external financing for future acquisitions.

Management Comments

• AngioDynamics is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by focusing on cardiovascular disease and cancer.
• Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion and customer centric sales performance.
• The current macroeconomic environment continues to impact our business and may continue to pose future risks.
• Management focuses on company-wide and segment revenue and gross margin and company-wide operating income, earnings per share and cash flow from operations in evaluating performance.

Industry Context

StockSavvy.ai notes that AngioDynamics operates in the competitive medical technology sector, facing trends such as healthcare provider consolidation, increased consumer involvement in healthcare decisions, and an aging population. The company's growth is influenced by regulatory changes, global economic fluctuations, and the introduction of new products, often through internal development, licensing, or strategic alliances.

Comparison to Industry Standards

• The company's gross margin of 59.4% is strong, particularly in the Med Tech segment (66.2%), which generally indicates efficient production and pricing power. However, this needs to be compared against specific benchmarks for medical device companies in similar sub-sectors (e.g., cardiovascular, oncology).
• The net loss of $7.1 million, despite revenue growth, suggests that operating expenses, particularly R&D and Sales & Marketing, are substantial and may be higher than industry averages for companies of similar size and growth stage.
• The decrease in cash reserves warrants monitoring, especially if the company plans significant capital expenditures or acquisitions without a clear path to profitability.
• The company's reliance on distributors for international sales is a common strategy, but can sometimes lead to lower margins compared to direct sales models.

Management Changes

Legal Proceedings

• C.R. Bard, Inc. v. AngioDynamics, Inc. related to patent infringement of implantable port products; judgment entered in favor of AngioDynamics on June 1, 2023.
• Bard filed suit asserting infringement of certain port products; settled on March 31, 2024, with AngioDynamics paying $7.0 million and agreeing to minimum annual payments and potential contingent payments.
• AngioDynamics filed a patent infringement lawsuit against Endovascular Engineering, Inc. (E2) on April 23, 2026, alleging infringement of its thrombectomy system patents.
• The company is defending approximately 430 product liability claims involving its port products, consolidated for pretrial proceedings.

Stakeholder Impact

• Shareholders: Continued net losses and a decrease in cash reserves may impact investor sentiment, although revenue growth and margin improvement are positive signs.
• Employees: Increased R&D and S&M expenses may indicate investment in growth and potential future opportunities, but ongoing restructuring and CEO transition could create uncertainty.
• Customers: The company's focus on expanding treatment options and improving patient outcomes aims to benefit healthcare providers and patients.
• Creditors: The company has no outstanding debt as of August 31, 2026, and has a revolving credit facility, suggesting a stable short-term liquidity position for creditors.

Next Steps

• Continue to focus on innovative R&D, clinical and regulatory pathway expansion, and customer-centric sales performance.
• Expand geographically and penetrate new markets.
• Introduce new products and increase international presence.
• Continue to evaluate the company's liquidity position and monitor customer and supplier actions.
• Management will continue to assess the level of the valuation allowance for deferred tax assets.

Key Dates

Recommendation

The company shows positive trends in revenue growth and gross margin improvement, indicating operational progress. However, the continued net loss, significant operating expenses, and decrease in cash reserves, coupled with a CEO transition, warrant a cautious 'hold' rating. Further clarity on the path to profitability and successful integration of new leadership will be key.

Keywords

medical technology, medical devices, cardiovascular disease, oncology, vascular access, thrombus management, revenue growth, gross margin